• 1
    Kohno N, Akiyama M, Kyoizumi S et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 20316.
  • 2
    Bowden DH. Alveolar response to injury. Thorax 1981; 36: 8014.
  • 3
    Kohno N, Kyoizumi S, Awaya Y et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 6873.
  • 4
    Kohno N, Hamada H, Fujioka S et al. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest 1992; 102: 11722.
  • 5
    Inoue Y, Barker E, Daniloff E et al. Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis. Am J Respir Crit Care Med 1997; 156: 10915.
  • 6
    Hamada H, Kohno N, Akiyama M et al. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest 1992; 101: 85860.
  • 7
    Hamada H, Kohno N, Hiwada K. A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma. Jpn J Cancer Res 1994; 85: 2119.
  • 8
    Kohno N, Inoue Y, Hamada H et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9 Int J Cancer Suppl 1994; 8: 813.
  • 9
    Oyama T, Kohno N, Yokoyama A et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung 1997; 175: 37985.
  • 10
    Yokoyama A, Kohno N, Hamada H et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 16804.
  • 11
    Fukaya S, Oshima H, Kato K et al. KL-6 as a novel marker for activities of interstitial pneumonia in connective tissue diseases. Rheumatol Int 2000; 19: 2235.
  • 12
    Nakajima H, Harigai M, Hara M et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol 2000; 27: 116470.
  • 13
    Arai Y, Obinata K, Sato Y et al. Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia. Eur J Pediatr 2001; 160: 4259.
  • 14
    Ohnshi H, Yokoyama A, Kondo K et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002; 165: 37881.
  • 15
    Ohnishi H, Yokoyama A, Yasuhara Y et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003; 58: 8725.
  • 16
    Yanaba K, Hasegawa M, Takehara K et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 111220.
  • 17
    Hara R, Itami J, Komiyama T et al. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung cancer. Chest 2004; 125: 3404.
  • 18
    American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277304.
  • 19
    Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 20
    Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 3447.
  • 21
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 22
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
  • 23
    Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 54854.
  • 24
    Kasukawa R, Tojo T, Miyawaki S et al. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: KasukawaR, SharpGC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam: Elsevier, 1987; 417.
  • 25
    McNeil BJ, Keller E, Adelstein SJ. Primer on certain elements of decision making. N Engl J Med 1975; 293: 2115.
  • 26
    Kohno N, Awaya Y, Oyama T et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 63742.
  • 27
    Takahashi T, Munakata M, Suzuki I et al. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1998; 158: 12948.
  • 28
    Ishizaka A, Matsuda T, Albertine KH et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2004; 286: L108894.
  • 29
    Sato H, Callister ME, Mumby S et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J 2004; 23: 1425.
  • 30
    Narita M, Nakayama M, Yamada S et al. Elevated KL-6 levels in fatal measles pneumonia. Eur J Pediatr 2001; 160: 4545.
  • 31
    Goto K, Kodama T, Sekine I et al. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 2001; 34: 1418.